RET inhibitor: Difference between revisions
CSV import |
CSV import |
||
| Line 30: | Line 30: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:PDB 7JU6.png|RET inhibitor | |||
File:Cabozantinib.svg|Cabozantinib | |||
File:Pralsetinib.svg|Pralsetinib | |||
</gallery> | |||
Latest revision as of 01:15, 20 February 2025
RET inhibitor is a type of drug that blocks the activity of RET proteins in cancer cells. RET proteins are involved in cell growth and division, cell movement, and the self-destruction of cells. By blocking these proteins, RET inhibitors can stop the growth and spread of cancer cells. RET inhibitors are used to treat certain types of thyroid cancer and lung cancer.
Mechanism of Action[edit]
RET inhibitors work by blocking the activity of RET proteins in cancer cells. These proteins are involved in several important processes in the cell, including cell growth and division, cell movement, and the self-destruction of cells. When these proteins are overactive or mutated, they can contribute to the development and progression of cancer. By blocking the activity of these proteins, RET inhibitors can stop the growth and spread of cancer cells.
Uses[edit]
RET inhibitors are used to treat certain types of thyroid cancer and lung cancer. They are often used when the cancer has spread to other parts of the body, or when other treatments have not worked.
Side Effects[edit]
Like all drugs, RET inhibitors can cause side effects. These can vary from person to person, and can include fatigue, constipation, dry mouth, and high blood pressure. It's important for patients to discuss these potential side effects with their healthcare provider before starting treatment.
Research[edit]
Research is ongoing to find new uses for RET inhibitors and to better understand how they work. This includes clinical trials to test new RET inhibitors, as well as studies to identify biomarkers that can predict who will respond to these drugs.
